Hemab Therapeutics Holdings, Inc. (COAG) — SEC Filings
Hemab Therapeutics Holdings, Inc. (COAG) — 3 SEC filings. Latest: 424B4 (May 1, 2026). Includes 1 424B4, 1 S-1MEF, 1 S-1/A. AI-decoded analysis.
View Hemab Therapeutics Holdings, Inc. on SEC EDGAR
Overview
Hemab Therapeutics Holdings, Inc. (COAG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B4 filed on May 1, 2026: Hemab Therapeutics Holdings, Inc. filed a 424B4 prospectus on May 1, 2026, detailing its intention to offer securities. The filing, with SEC Accession No. 0001193125-26-201458, provides information for potential investors regarding the company's offerings. Hemab Therapeutics Holdings, Inc. is based
Sentiment Summary
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant filing sentiment for Hemab Therapeutics Holdings, Inc. is neutral.
Filing Type Overview
Hemab Therapeutics Holdings, Inc. (COAG) has filed 1 424B4, 1 S-1MEF, 1 S-1/A with the SEC between Apr 2026 to May 2026.
Recent SEC Filings (3)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 1, 2026 | 424B4 | Hemab Therapeutics Holdings, Inc. Files 424B4 Prospectus | medium |
| Apr 30, 2026 | S-1MEF | S-1MEF Filing | |
| Apr 27, 2026 | S-1/A | S-1/A Filing |
Risk Profile
Risk Assessment: Of COAG's 1 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Top Tags
prospectus (1) · offering (1) · sec-filing (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 2026-05-01 | Date the 424B4 prospectus was filed and accepted. |
Frequently Asked Questions
What are the latest SEC filings for Hemab Therapeutics Holdings, Inc. (COAG)?
Hemab Therapeutics Holdings, Inc. has 3 recent SEC filings from Apr 2026 to May 2026, including 1 424B4, 1 S-1MEF, 1 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of COAG filings?
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant sentiment is neutral.
Where can I find Hemab Therapeutics Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hemab Therapeutics Holdings, Inc. (COAG) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hemab Therapeutics Holdings, Inc.?
Financial highlights for Hemab Therapeutics Holdings, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for COAG?
Investment thesis data for COAG will be available once enriched filings are processed.
Who are the key executives at Hemab Therapeutics Holdings, Inc.?
Executive information for Hemab Therapeutics Holdings, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Hemab Therapeutics Holdings, Inc. stock?
Of COAG's 1 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Hemab Therapeutics Holdings, Inc.?
Forward guidance and predictions for Hemab Therapeutics Holdings, Inc. are extracted from SEC filings as they are enriched.